Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The aim of the research was to assess possible histopathological differences between BRCA1- and BRCA2-associated malignant intraperitoneal (ovarian/fallopian tube/peritoneal) tumors and their sporadic counterparts. Dutch families harboring pathogenic BRCA1 or BRCA2 mutations were selected. Included were patients who had had malignant primary ovarian, fallopian tube or peritoneal tumors. Histopathological data was compared with data obtained from the Dutch cancer registry between 1989 and 1993 (reference group). A total of 63 with primary intraperitoneal malignant tumors were identified in 41 families. Non-epithelial malignant tumors were not observed in the study group versus 6% (n = 404) in the reference group (n = 6,789, P = 0.04). These tumors were excluded from further analysis, as were ovarian adenocarcinomas not otherwise specified, since these were detected in 22% of the study group, and in 19% of the reference group (P = 0.76). Serous carcinomas were detected in 94% (47/50) of the women in the study group in contrast to 62% (3,145/5,088) of the reference group (P < 0.01). In the study group, mucinous and endometrioid ovarian adenocarcinomas and serous ovarian borderline tumors each comprised 2.0% of the tumors. Clear cell ovarian carcinomas were not detected. In contrast, these percentages were 16% (P < 0.01), 10% (P = 0.07), 7% (P = 0.16) and 5% (P = 0.12), respectively, in the reference group. In the study group, 6.0% of the carcinomas arose in the fallopian tube versus 1.9% in the reference group (P = 0.03). Four percent of the study group developed primary serous peritoneal carcinomas, versus six percent in the reference group (P = 0.57). Serous carcinoma is the predominant type of intraperitoneal malignancy occurring in women harboring BRCA1 or BRCA2 mutations. Non-epithelial cancer does not seem to be part of the tumor spectrum of BRCA mutation carriers. This suggests, therefore, that serous tumors may be the only subtype related to a BRCA1 or BRCA2 mutation. Furthermore, fallopian tube carcinoma occurred more often in BRCA mutation carriers than in the reference population.
- Feunteun J, Lenoir GM. BRCA1, a gene involved in inherited predisposition to breast and ovarian cancer. Biochim Biophys Acta 1996; 1242(3): 177–80.
- Zweemer RP, van Diest PJ, Verheijen RH et al. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol 2000; 76: 45–50. CrossRef
- Bandera CA, Muto MG, Schorge JO et al. BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum. Obstet Gynecol 1998; 92: 596–600. CrossRef
- Schorge JO, Muto MG, Welch WR et al. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst 1998; 90(11): 841–5. CrossRef
- Rubin SC, Benjamin I, Behbakht K et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996; 335(19): 1413–6. CrossRef
- Johannsson O, Ranstam J, Borg A, Olsson H. BRCA1 mutations and survival in women with ovarian cancer. N Engl J Med 1997; 336(17): 1255–6.
- Stratton JF, Gayther SA, Russell P et al. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 1997; 336: 1125–30. CrossRef
- Boyd J, Sonoda Y, Federici MG et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000; 283(17): 2260–5. CrossRef
- Zweemer RP, Verheijen RH, Menko FH et al. Differences between hereditary and sporadic ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1999; 82(2): 151–3. CrossRef
- Risch HA, McLaughlin JR, Cole DEC et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001; 86: 700–10. CrossRef
- Shaw PA, McLaughlin JR, Zweemer RP et al. Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol 2002; 21(4): 407–11. CrossRef
- Piver MS. Hereditary ovarian cancer. Lessons from the first twenty years of the Gilda Radner Familial Ovarian Cancer Registry. Gynecol Oncol 2002; 85(1): 9–17. CrossRef
- Yazici H, Glendon G, Yazici H et al. BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in non-familial cases. Hum Mutat 2002; 20(1): 28–34. CrossRef
- Zweemer RP, Verheijen RH, Gille JJ et al. Clinical and genetic evaluation of thirty ovarian cancer families. Am J Obstet Gynecol 1998; 178: 85–90. CrossRef
- Visser O, Coebergh JW, Otter R (eds). Gynaecological Tumours in The Netherlands. Association of Comprehensive Cancer Centers Utrecht. Almelo, The Netherlands: Lulof, 1997: 1–26.
- Werness BA, Ramus SJ, Whittemore AS et al. Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations. Hum Pathol 2000; 31(11): 1420–4. CrossRef
- Piura B, Rabinovich A, Yanai-Inbar I. Three primary malignancies related to BRCA mutation successively occurring in a BRCA1 185delAG mutation carrier. Eur J Obstet Gynecol Reprod Biol 2001; 97(2): 241–4. CrossRef
- Piek JM, van Diest PJ, Zweemer RP et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001; 195(4): 451–6. CrossRef
- Agoff SN, Mendelin JE, Grieco VS, Garcia RL. Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or-2 mutations: implications for gross examination, cytology, and clinical follow-up. Am J Surg Pathol 2002; 26(2): 171–8. CrossRef
- Woolas R, Jacobs I, Prys Davies A et al. What is the true incidence of fallopian tube carcinoma? Int J Gynecol Cancer 1994; 4(6): 384–8 CrossRef
- Colgan TJ. Challenges in the early diagnosis and staging of fallopian-tube carcinomas associated with BRCA mutations. Int J Gynecol Pathol 2003; 22(2): 109–20. CrossRef
- Eeles R, Piver S, Piek JM et al. Inherited tumour syndromes. In Tavasolli F, Devilee P (eds), WHO Classification of Gynaecological Tumours. Lyon: IARC Press (in press).
- Hu CY, Taymor ML, Hertig AT. Primary carcinoma of the fallopian tube. Am J Obstet Gynecol 1950; 59: 58.
- Woolas R, Smith J, Paterson JM, Sharp F. Fallopian tube carcinoma: an under-recognized primary neoplasm. Int J Gynecol Cancer 1997; 7: 284–8. CrossRef
- Piek JM, van Diest PJ, Zweemer RP et al. Tubal ligation and risk of ovarian cancer. Lancet 2001; 358(9284): 844–5. CrossRef
- Levene S, Scott G, Price P et al. Does the occurrence of certa in rare cancers indicate an inherited cancer susceptibility? Familial Cancer 2003; 2: 15–25. CrossRef
- Schorge JO, Muto MG, Lee SJ et al. BRCA1-related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis. Cancer Res 2000; 60(5): 1361–4.
- Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study
Volume 2, Issue 2 , pp 73-78
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers
- Additional Links
- fallopian tube carcinoma
- ovarian carcinoma
- Industry Sectors
- Author Affiliations
- 1. Departments of Obstetrics and Gynaecology, VU University Medical Center, Amsterdam, The Netherlands
- 2. Departments of Clinical Genetics and Human Genetics, VU University Medical Center, Amsterdam, The Netherlands
- 3. Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands